Interventional treatment of acute right ventricular outflow track (RVOT) infectious endocarditis as bridge to surgery or percutaneous pulmonary valve implantation

IF 2.3 3区 医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS Archives of Cardiovascular Diseases Pub Date : 2024-08-01 DOI:10.1016/j.acvd.2024.07.029
A. Callegari , M. Albertini , L. Iserin , D. Bonnet , S. Malekzadeh-Milani
{"title":"Interventional treatment of acute right ventricular outflow track (RVOT) infectious endocarditis as bridge to surgery or percutaneous pulmonary valve implantation","authors":"A. Callegari ,&nbsp;M. Albertini ,&nbsp;L. Iserin ,&nbsp;D. Bonnet ,&nbsp;S. Malekzadeh-Milani","doi":"10.1016/j.acvd.2024.07.029","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><p>Infectious endocarditis (IE) is life threatening after pulmonary valve replacement. In case of obstructive cardiogenic shock or severe RVOTO an emergency percutaneous treatment can allow clinical stabilization to delay valve replacement.</p></div><div><h3>Objective</h3><p>This study aims to assess procedural success and clinical outcome in 16 consecutive patients (mean<!--> <!-->±<!--> <!-->SD age 27.2<!--> <!-->±<!--> <!-->15.7) with IE and primary percutaneous treatment.</p></div><div><h3>Methods</h3><p>Patients were retrospectively included.</p></div><div><h3>Results</h3><p>IE affected a Melody® valve in 9/16 (57%) cases (3/9 in a native RVOT, 1/9 with a Melody® valve in each PA, 1/9 in a Contegra VenPro™, 2/9 in a Hancock® bioprosthesis, 2/9 in a pulmonary homograft); a Contegra VenPro™ in 6/16 (37%); and a BioPulmonic Valve™ in 1/16 (6%).</p><p>Diagnosis of IE was 58.1<!--> <!-->±<!--> <!-->34.3<!--> <!-->months after last intervention/surgery and delay from diagnosis of IE to emergency percutaneous treatment was 9.8<!--> <!-->±<!--> <!-->13.5<!--> <!-->days. Clinical presentation was obstructive cardiogenic shock in 50%, septic shock in 25% or fever/shivering with severe RVOTO in 25%. At time of intervention 68% had an active bacteremia. On echo RVOT velocity was 4.6<!--> <!-->±<!--> <!-->0.4<!--> <!-->m/s and RV function was severely reduced in 68%.</p><p>Procedural time was 76<!--> <!-->±<!--> <!-->48<!--> <!-->min. Invasive RV-systolic-pressure 86<!--> <!-->±<!--> <!-->21<!--> <!-->mmHg, mean-PA pressure 19<!--> <!-->±<!--> <!-->5<!--> <!-->mmHg, and systolic-aortic-pressure 95<!--> <!-->±<!--> <!-->13<!--> <!-->mmHg. Procedural approach (<span><span>Table 1</span></span>) was dilatation in 3 patients, uncovered-stent implantation in 5, covered-stent implantation in 7, Melody® valve in 1.</p><p>Immediate resolution of the RVOTO was obtained in all patients. Post-procedural systolic-RV-pressure was 42<!--> <!-->±<!--> <!-->11<!--> <!-->mmHg, while RVOT systolic gradient was 19<!--> <!-->±<!--> <!-->7<!--> <!-->mmHg. There were no periprocedural deaths but one severe complication (rupture of a tricuspid valve corda, repaired with the following surgery).</p><p>Surgical repair (68%) and percutaneous pulmonary valve implantation (18%) were performed after 12<!--> <!-->±<!--> <!-->34 months. One patient died of IE relapse after 3-months and one during surgery. One had cardiac transplantation due to uncontrolled sepsis.</p></div><div><h3>Conclusion</h3><p>Emergency interventional relieve of RVOTO was effective in all patients and permitted to delay pulmonary valve replacement in these critically ill patients.</p></div>","PeriodicalId":55472,"journal":{"name":"Archives of Cardiovascular Diseases","volume":null,"pages":null},"PeriodicalIF":2.3000,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Archives of Cardiovascular Diseases","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S187521362400250X","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction

Infectious endocarditis (IE) is life threatening after pulmonary valve replacement. In case of obstructive cardiogenic shock or severe RVOTO an emergency percutaneous treatment can allow clinical stabilization to delay valve replacement.

Objective

This study aims to assess procedural success and clinical outcome in 16 consecutive patients (mean ± SD age 27.2 ± 15.7) with IE and primary percutaneous treatment.

Methods

Patients were retrospectively included.

Results

IE affected a Melody® valve in 9/16 (57%) cases (3/9 in a native RVOT, 1/9 with a Melody® valve in each PA, 1/9 in a Contegra VenPro™, 2/9 in a Hancock® bioprosthesis, 2/9 in a pulmonary homograft); a Contegra VenPro™ in 6/16 (37%); and a BioPulmonic Valve™ in 1/16 (6%).

Diagnosis of IE was 58.1 ± 34.3 months after last intervention/surgery and delay from diagnosis of IE to emergency percutaneous treatment was 9.8 ± 13.5 days. Clinical presentation was obstructive cardiogenic shock in 50%, septic shock in 25% or fever/shivering with severe RVOTO in 25%. At time of intervention 68% had an active bacteremia. On echo RVOT velocity was 4.6 ± 0.4 m/s and RV function was severely reduced in 68%.

Procedural time was 76 ± 48 min. Invasive RV-systolic-pressure 86 ± 21 mmHg, mean-PA pressure 19 ± 5 mmHg, and systolic-aortic-pressure 95 ± 13 mmHg. Procedural approach (Table 1) was dilatation in 3 patients, uncovered-stent implantation in 5, covered-stent implantation in 7, Melody® valve in 1.

Immediate resolution of the RVOTO was obtained in all patients. Post-procedural systolic-RV-pressure was 42 ± 11 mmHg, while RVOT systolic gradient was 19 ± 7 mmHg. There were no periprocedural deaths but one severe complication (rupture of a tricuspid valve corda, repaired with the following surgery).

Surgical repair (68%) and percutaneous pulmonary valve implantation (18%) were performed after 12 ± 34 months. One patient died of IE relapse after 3-months and one during surgery. One had cardiac transplantation due to uncontrolled sepsis.

Conclusion

Emergency interventional relieve of RVOTO was effective in all patients and permitted to delay pulmonary valve replacement in these critically ill patients.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
急性右心室流出道(RVOT)感染性心内膜炎的介入治疗,为手术或经皮肺动脉瓣植入术架起桥梁
导言感染性心内膜炎(IE)在肺动脉瓣置换术后会危及生命。本研究旨在评估连续 16 例 IE 患者(平均 ± SD 年龄 27.2 ± 15.7)的手术成功率和临床预后。结果IE影响Melody®瓣膜的病例有9/16(57%)(3/9在原生RVOT中,1/9在每个PA中使用Melody®瓣膜,1/9在Contegra VenPro™中,2/9在Hancock®生物瓣膜中,2/9在肺同种移植中);影响Contegra VenPro™的病例有6/16(37%);影响BioPulmonic Valve™的病例有1/16(6%)。IE的诊断时间为上次介入/手术后58.1 ± 34.3个月,从诊断IE到紧急经皮治疗的延迟时间为9.8 ± 13.5天。临床表现为阻塞性心源性休克(50%)、脓毒性休克(25%)或发热/颤抖伴严重RVOTO(25%)。介入治疗时,68%的患者患有活动性菌血症。手术时间为 76 ± 48 分钟。侵入性 RV 收缩压为 86 ± 21 mmHg,PA 平均压为 19 ± 5 mmHg,主动脉收缩压为 95 ± 13 mmHg。手术方法(表 1):3 例患者采用扩张术,5 例患者采用覆盖支架植入术,7 例患者采用覆盖支架植入术,1 例患者采用 Melody® 瓣膜。术后收缩压为(42 ± 11)毫米汞柱,而 RVOT 收缩阶差为(19 ± 7)毫米汞柱。手术前后无死亡病例,但发生了一起严重并发症(三尖瓣心索破裂,后经手术修复)。一名患者在 3 个月后因 IE 复发而死亡,一名患者在手术期间死亡。结论紧急介入缓解RVOTO对所有患者都有效,可以推迟这些重症患者的肺动脉瓣置换术。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Archives of Cardiovascular Diseases
Archives of Cardiovascular Diseases 医学-心血管系统
CiteScore
4.40
自引率
6.70%
发文量
87
审稿时长
34 days
期刊介绍: The Journal publishes original peer-reviewed clinical and research articles, epidemiological studies, new methodological clinical approaches, review articles and editorials. Topics covered include coronary artery and valve diseases, interventional and pediatric cardiology, cardiovascular surgery, cardiomyopathy and heart failure, arrhythmias and stimulation, cardiovascular imaging, vascular medicine and hypertension, epidemiology and risk factors, and large multicenter studies. Archives of Cardiovascular Diseases also publishes abstracts of papers presented at the annual sessions of the Journées Européennes de la Société Française de Cardiologie and the guidelines edited by the French Society of Cardiology.
期刊最新文献
Cardiac magnetic resonance imaging-derived right ventricular volume and function, and association with outcomes in isolated tricuspid regurgitation. Should SGLT2 inhibitors be prescribed after myocardial infarction with left ventricular dysfunction? Response to a letter from Modumudi et al. commenting on the article "Cardiogenic shock and infection: A lethal combination". 2023 SFMU/GICC-SFC/SFGG expert recommendations for the emergency management of older patients with acute heart failure. Part 2: Therapeutics, pathway of care and ethics. Letter commenting on the article entitled "Cardiogenic shock and infection: A lethal combination" by Cherbi et al.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1